This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Most colorectal cancers are microsatellite-stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies. Coinhibition of anti-PD-1 and STAT3 can elicit an effective antitumor response in a small subset of patients with microsatellite-stable colorectal cancer, and biomarkers predictive of response are under investigation.
See related article by Kawazoe et al., p. 5887
Footnotes
Clin Cancer Res 2020;26:5775–7
- Received August 26, 2020.
- Revision received September 9, 2020.
- Accepted September 16, 2020.
- Published first September 21, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
November 2020
Volume 26, Issue 22
Volume 26, Issue 22
Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
Jump to section
Advertisement